NCT07598617 The Co-Production and Evaluation of the Computerised Cognitive Assessment for Preclinical Alzheimer's Disease (CoCoA-PAD)
| NCT ID | NCT07598617 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Plymouth |
| Condition | Alzheimer Disease (AD) |
| Study Type | OBSERVATIONAL |
| Enrollment | 120 participants |
| Start Date | 2026-05-05 |
| Primary Completion | 2028-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 120 participants in total. It began in 2026-05-05 with a primary completion date of 2028-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Background. Healthcare professionals can now diagnose the earliest stages of Alzheimer's disease (early-AD) and new drugs are effective at slowing the disease. The National Health Service (NHS) in the United Kingdom has started to develop plans for how to implement these key achievements into clinical practice, so that patients can receive timely diagnosis and treatment. Cognitive assessments measure someone's memory and thinking skills and are required for an early-AD diagnosis. There are concerns that the NHS does not have the workforce to deliver cognitive assessments, and that this will delay early-AD diagnosis and treatment. Memory nurses are the largest staffing group in memory services. I have developed a plan for memory nurses to deliver full cognitive assessments. This would prevent delays to early diagnosis and treatment. Research Aims. This research will use a co-design approach. This involves working with service users and memory nurses to co-develop and evaluate a new cognitive assessment and cognitive training course for nurses. Research Methods. The cognitive assessment and training course will be evaluated using service-user and nurse feedback. 120 older adults with subjective memory complaints will be asked to complete a cognitive assessment, a brain scan, and a blood test. We will use this information to tell us if the cognitive assessment is good enough. Patient and Public Involvement. This proposal was co-developed with older adults and memory nurses. The adapted cognitive assessment and the cognitive training will be co-created with ten older adults and five memory-nurses, who will consult on all stages of the project. Dissemination. The research findings will be published in academic journals and conferences, and an information-sheet will be created for the public. The cognitive training resources will be made freely available. We will use the results of this research to request funding to translate the cognitive assessment into an NHS approved health-technology.
Eligibility Criteria
Recruitment Criteria for Subjective Cognitive Decline and Mild Cognitive Impairment Subjective Cognitive Decline Inclusion Criteria * \>3.38 on IQCODE Self-Report items 1-7 (PROTECT) OR * ≥4 on SCD-Q9 (non-Protect) AND * Age ≥65 years * Onset of SCD within the last 5 years * English as a first language * Normal demographically adjusted performance on standardised cognitive tests * Specific Race and Education (using stratified sampling approach) Exclusion Criteria * Cognitive impairment, i.e., performance ≥1 SD below demographically adjusted norms (PROTECT) OR * ≤17 on the telephone MoCA (non-PROTECT) AND * Lacks mental capacity to consent to research * Diagnosis of dementia * Sensory impairment that cannot be corrected for with sensory aids, e.g., blindness. * Previous neurological injury (stroke, traumatic brain injury, severe epilepsy, brain tumour) * Other neurodegenerative syndrome (e.g., Parkinson's disease, multiple sclerosis, etc) * Diagnosis of learning disability * Severe depression (PHQ-9≥15 OR score ≥1 on PHQ-9 suicide question * Current severe psychiatric disorder (bipolar disorder, schizophrenia, or psychotic disorders) * Current drug or alcohol abuse * Untreated diagnosis of sleep apnoea. Mild Cognitive Impairment Inclusion Criteria * \>3.38 on IQCODE Self-Report items 1-7 (PROTECT) * Cognitive impairment, i.e., performance ≥1 SD below demographically adjusted norms (PROTECT) OR * ≥4 on SCD-Q9 (non-PROTECT) * ≤17 on the telephone MoCA (non-PROTECT) OR * MCI diagnosis according to DSM or ICD-11 criteria through an NHS memory clinic. AND * Age ≥65 years * Onset of SCD within the last 5 years * English as a first language * Specific Race and Education (using stratified sampling approach) Exclusion Criteria * A score of ≥3 on any item on the Instrumental Activities of Daily Living scale, subject to clinical judgement. * Lacks mental capacity to consent to research * Diagnosis of dementia * Sensory impairment that cannot be corrected for with sensory aids, e.g., blindness. * Previous neurological injury (stroke, traumatic brain injury, severe epilepsy, brain tumour) * Other neurodegenerative syndrome (e.g., Parkinson's disease, multiple sclerosis, etc) * Diagnosis of learning disability * Severe depression (PHQ-9≥15 OR score ≥1 on PHQ-9 suicide question * Current severe psychiatric disorder (bipolar disorder, schizophrenia, or psychotic disorders) * Current drug or alcohol abuse * Untreated diagnosis of sleep apnoea.
Contact & Investigator
Nicolas Farina, PhD
STUDY DIRECTOR
University of Plymouth
Frequently Asked Questions
Who can join the NCT07598617 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, studying Alzheimer Disease (AD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07598617 currently recruiting?
Yes, NCT07598617 is actively recruiting participants. Contact the research team at donnchadh.murphy@plymouth.ac.uk for enrollment information.
Where is the NCT07598617 trial being conducted?
This trial is being conducted at Plymouth, United Kingdom, Exeter, United Kingdom, London, United Kingdom.
Who is sponsoring the NCT07598617 clinical trial?
NCT07598617 is sponsored by University of Plymouth. The principal investigator is Nicolas Farina, PhD at University of Plymouth. The trial plans to enroll 120 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.